Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eklira

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

UCB’s chair Gerhard Mayr joins Almirall board

He becomes an independent director of the Spanish pharma company

Novartis’ COPD drug Seebri cleared in EU and Japan

Used with Breezhaler device in Europe and inhalation capsule in Japan

Almirall’s IBS drug Constella backed by CHMP

On track to become the first drug specifically approved for the condition

Novartis building

Novartis showcases COPD candidates at ERS meeting

Positive results for three late-stage drugs

- PMLiVE

COPD-asthma cases set to grow in Europe as people live longer

Study also highlights the respiratory burden the elderly will face

- PMLiVE

COPD needs to learn risk reductions lessons from heart disease

Takeda-backed report says HCPs working in COPD need to learn from progress made by their colleagues in cardiovascular medicine

- PMLiVE

European Commission wants tougher anti-smoking measures to halt spread of chronic diseases

Large number of young smokers will lead to further problems says EC's Martin Seychell at ERS congress

- PMLiVE

Almirall strikes UK commercial partnership with Quintiles

Agreement will focus on the promotion of Almirall's respiratory portfolio in the UK

- PMLiVE

Interview: Jorge Gallardo, Almirall

The executive chairman of Spanish pharmaceutical company Almirall explains to PME editor Linda Banks how bold investment in R&D and international expansion are key to the company's growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links